Literature DB >> 17269991

The quantitative validation of non-endoscopic disease activity indices in ulcerative colitis.

P D R Higgins1, J Leung, M Schwartz, J Mapili, P A Wren, E M Zimmermann.   

Abstract

BACKGROUND: Ulcerative colitis disease activity indices have not been formally validated. AIM: To analise quantitatively the psychometric and performance validity of two non-endoscopic indices for ulcerative colitis, the Simple Clinical Colitis Activity Index and the Seo Index.
METHODS: In 66 patients with ulcerative colitis, the measurement of disease activity was repeated with the two non-endoscopic indices, St Mark's Index, and the Inflammatory Bowel Disease Questionnaire. Psychometric validity was evaluated by measuring the content, construct, criterion-convergent and criterion-predictive validity on a 0-1 scale. Performance validity was evaluated by measuring the reproducibility and responsiveness on a 0-1 scale.
RESULTS: The Simple Clinical Colitis Activity Index had good to excellent psychometric and performance validity, while the Seo Index had moderate to excellent psychometric validity and moderate to good performance validity. The Simple Clinical Colitis Activity Index had weaknesses in content validity and in responsiveness. The Seo Index had weaknesses in content validity, construct validity and responsiveness.
CONCLUSIONS: These two non-endoscopic indices for ulcerative colitis have good psychometric and performance validity, and are now the most rigorously validated disease activity indices for ulcerative colitis. The Simple Clinical Colitis Activity Index appears to have better overall validity. Quantitative evaluation identifies weaknesses in disease activity indices, and can lead to better disease activity indices for ulcerative colitis.

Entities:  

Mesh:

Year:  2007        PMID: 17269991     DOI: 10.1111/j.1365-2036.2006.03205.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  4 in total

1.  Patient perception of chronic illness care in a large inflammatory bowel disease cohort.

Authors:  Rachel L Randell; Millie D Long; Christopher F Martin; Robert S Sandler; Wenli Chen; Kristen Anton; Michael D Kappelman
Journal:  Inflamm Bowel Dis       Date:  2013-06       Impact factor: 5.325

2.  B lymphocyte intestinal homing in inflammatory bowel disease.

Authors:  Caterina Defendenti; Piercarlo Sarzi-Puttini; Silvia Grosso; Annamaria Croce; Olivia Senesi; Simone Saibeni; Simona Bollani; Piero Luigi Almasio; Savino Bruno; Fabiola Atzeni
Journal:  BMC Immunol       Date:  2011-12-30       Impact factor: 3.615

3.  First multicenter study of modified release phosphatidylcholine "LT-02" in ulcerative colitis: a randomized, placebo-controlled trial in mesalazine-refractory courses.

Authors:  Max Karner; Andreas Kocjan; Juergen Stein; Stefan Schreiber; Georg von Boyen; Peter Uebel; Carsten Schmidt; Limas Kupcinskas; Ion Dina; Frank Zuelch; Gerhard Keilhauer; Wolfgang Stremmel
Journal:  Am J Gastroenterol       Date:  2014-05-06       Impact factor: 10.864

4.  Effect of Adalimumab on Clinical Outcomes and Health-related Quality of Life Among Patients With Ulcerative Colitis in a Clinical Practice Setting: Results From InspirADA.

Authors:  Simon Travis; Brian G Feagan; Laurent Peyrin-Biroulet; Remo Panaccione; Silvio Danese; Andreas Lazar; Anne M Robinson; Joel Petersson; Brandee L Pappalardo; Mareike Bereswill; Naijun Chen; Song Wang; Martha Skup; Roopal B Thakkar; Jingdong Chao
Journal:  J Crohns Colitis       Date:  2017-10-27       Impact factor: 9.071

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.